Research Overview
Across the abstracts, Clostridium butyricum is most frequently studied as a butyrate-producing gut commensal used as a probiotic, with research spanning gastrointestinal disorders (infectious diarrhea, intestinal injury, irritable bowel syndrome, inflammatory bowel disease), metabolic and liver–adipose axis outcomes, neurodegenerative disease links, and cancer—particularly colorectal cancer (CRC). Mechanistic work is a major emphasis: proposed benefits are commonly attributed to microbial metabolites (especially butyrate and other short-chain fatty acids), modulation of host immune and inflammatory signaling (e.g., MAPK and NF-κB pathways), effects on epithelial barrier integrity, and broader downstream impacts beyond the gut. Several studies also examine microbiome remodeling (changes in community diversity and pathogen abundance) and metabolomic shifts (e.g., amino acid and tryptophan-related pathways), including in animal agriculture models such as weaned piglets.
The strongest evidence in these abstracts supports (i) a generally favorable safety profile for established non-toxigenic probiotic strains used clinically for decades, and (ii) biologically plausible anti-inflammatory and barrier-protective effects in preclinical models, particularly for colitis/IBD. Notably, one study highlights C. butyricum-derived extracellular vesicles as a mechanistically defined intervention in experimental colitis, linking benefit to restoration of miR-199a-3p and suppression of proinflammatory signaling, alongside reductions in potential pathogens and changes in tryptophan metabolites. Evidence for anti-tumor effects is also present but remains largely preclinical (e.g., inhibition of high-fat-diet–associated intestinal tumor development in an Apc-related model), supporting the concept that restoring butyrate-producing capacity may counter dysbiosis-associated carcinogenesis.
Key gaps center on strain-level heterogeneity and translation to humans. Multiple abstracts emphasize that while non-toxigenic strains are used as probiotics, other C. butyricum strains can be pathogenic, including rare association with botulism (via neurotoxin production in related clostridia and occasionally C. butyricum) and links to necrotizing enterocolitis in preterm neonates; genome sequencing has identified toxin genes in some strains and asymptomatic carriage can occur. Consequently, more research is needed to (i) delineate which strains and genetic features confer benefit versus risk, (ii) establish standardized manufacturing/quality controls and surveillance for toxigenic determinants, and (iii) conduct additional well-powered human randomized controlled trials to confirm efficacy across indications (IBD, CRC prevention/adjunctive care, and other systemic outcomes) and to define optimal dosing, duration, and patient subgroups most likely to benefit.
1. What conditions has C. butyricum been studied for?
Gastrointestinal infections and dysbiosis-related illness: including Clostridioides difficile, Helicobacter pylori, and antibiotic-resistant Escherichia coli (review of GI infections; CBM 588 highlighted).
Inflammatory bowel disease (IBD) / colitis: discussed as a future “microbiological treatment” for IBD; multiple preclinical colitis models including DSS-induced colitis in mice; also studied via C. butyricum-derived extracellular vesicles (CbEVs) in ulcerative colitis models.
Colorectal cancer (CRC) / intestinal tumorigenesis: reduction of butyrate-producers noted in CRC patients; C. butyricum tested in an Apc-related intestinal tumor model with high-fat diet (HFD)-induced tumor development (animal model).
Irritable bowel syndrome (IBS) and intestinal injury: listed among conditions investigated in a broad review of supplementation.
Metabolic disease: listed in the broad review as an investigated area (details not provided in the supplied abstracts).
Neurodegenerative disease: listed in the broad review; Parkinson’s disease is mentioned in the context of engineered microorganisms (not enough detail in the provided text to conclude efficacy).
Postoperative recovery after gastrectomy (gastric cancer surgery): a clinical trial is referenced but the abstract is truncated, so the intervention and outcomes cannot be extracted from the provided text.
Veterinary/animal production contexts: weaning stress and gut health in piglets; growth and immune function in shrimp; aquaculture applications (reviews and feeding studies).
Safety/pathogenicity contexts: botulism (rarely caused by C. butyricum strains producing botulinum neurotoxin); necrotizing enterocolitis (NEC) in preterm neonates linked to certain strains (overview of beneficial vs pathogenic strains).
2. Does it work in treating those conditions? Summarize the evidence.
-
IBD/colitis (preclinical evidence):
CbEVs improved inflammation in an in vitro LPS-stimulated macrophage model and an in vivo DSS-induced colitis mouse model, with mechanistic links to restoring miR-199a-3p and suppressing MAPK and NF-κB signaling; metagenomics showed reduced abundance of potential pathogens (E. coli, Shigella flexneri) and changes in tryptophan metabolites associated with improved barrier integrity (mouse data).
Another DSS-induced acute ulcerative colitis mouse study reported that C. butyricum and/or chitooligosaccharides (COS) ameliorated UC symptoms (details truncated but direction of effect stated).
Limitations: these are animal and cell-model findings; the provided abstracts do not include robust human randomized controlled trial (RCT) outcomes for IBD.
-
Colorectal cancer / intestinal tumors (preclinical evidence):
In an Apc-related model, C. butyricum significantly inhibited HFD-induced intestinal tumor development (animal model). Human benefit is plausible but not established by these abstracts.
-
GI infections (mixed evidence; largely review-based in provided text):
A review focused on GI infections states C. butyricum (including CBM 588) is “widely effective” against C. difficile, H. pylori, and antibiotic-resistant E. coli, and emphasizes mechanisms related to dysbiosis correction and inhibition of resistant gene transmission.
However, the supplied text does not provide specific human RCT endpoints, effect sizes, or study designs; thus, efficacy in humans cannot be confirmed from these abstracts alone.
-
Piglet weaning stress / diarrhea (animal evidence):
In weaned piglets, C. butyricum did not significantly change growth performance or diarrhea incidence over 0–21 days, but it increased microbiome richness (ACE/Chao) and altered taxa and fecal metabolites (animal production context; not direct clinical translation).
-
Other areas (IBS, metabolic disease, neurodegeneration, postoperative recovery):
A broad review states these have been investigated, but the provided abstracts do not include enough outcome data to judge whether it “works” for these indications.
The broad review explicitly notes that additional human randomized controlled trials are needed.
3. What health benefits does it have?
Butyrate production: repeatedly emphasized as central to proposed benefits; butyrate is highlighted as a key molecular signal mediating downstream effects beyond the gut (review).
Immune and inflammatory regulation: proposed “immunological signals in the digestive system” with systemic effects (review). In colitis models, CbEVs suppressed pro-inflammatory MAPK and NF-κB signaling via a microRNA-linked mechanism (miR-199a-3p/map3k4 axis).
Gut barrier and microbiome support:
CbEVs improved intestinal barrier integrity in colitis mice and reduced dysbiosis, including lowering E. coli and Shigella flexneri abundance (mouse data).
In piglets, supplementation increased microbial richness and shifted taxa (e.g., increased Megasphaera and certain Ruminococcaceae/Prevotellaceae groups) and altered fecal metabolites (amino acid and tryptophan-related pathways), consistent with microbiome functional changes.
Antagonism against pathogens / infection-related benefits: a review describes clinical/veterinary use for GI infections and suggests it may help maintain microbiome homeostasis during antibiotic-associated dysbiosis and potentially reduce transmission of antibiotic-resistance genes (positioned as an AMR/One Health countermeasure).
Spore formation and resilience: described as a spore-former and, in piglet-focused work, noted to be resistant to high temperature, acid, bile salts, and some antibiotics—traits that may support survivability through the GI tract (though survivability is not the same as clinical efficacy).
4. Does it have any downsides or side effects?
-
Strain-dependent pathogenic potential:
While “safety of probiotic C. butyricum strains appears well-established” (review), another abstract emphasizes that within the same species, different strains can be beneficial or pathogenic.
Botulism risk (rare): botulinum neurotoxin is produced mainly by C. botulinum, but “rarely” by related species including C. butyricum; intestinal colonization botulism is described (guideline abstract). This is a serious but uncommon hazard and pertains to toxigenic strains, not standard probiotic strains.
Necrotizing enterocolitis (NEC) association in preterm neonates: certain C. butyricum strains have been implicated in NEC; genome sequencing has identified toxin genes in pathological strains, and asymptomatic carriage has been reported (overview abstract). This highlights the importance of strain selection and screening.
“Paradoxical” dose-dependent effects of short-chain fatty acids: an overview notes short-chain fatty acids can have a “dose-dependent paradoxical effect” on intestinal mucosa, implying that context and dosing may matter (details not provided in the abstract).
Evidence gaps for adverse event rates in humans: the provided abstracts do not quantify side-effect frequencies from human trials; therefore, beyond the strain-dependent risks above, the human tolerability profile cannot be fully characterized from these abstracts alone.
5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?
The provided abstracts do not report pharmacogenomic findings (i.e., differential benefits/harms based on human genetic variants). They do include:
Host genetics in animal disease models: an Apc-related intestinal tumor model is mentioned for tumor suppression under high-fat diet conditions, but this is a research model of tumor predisposition rather than evidence that specific human genotypes predict response to supplementation.
Microbial genetics (strain-level toxin genes): genome sequencing has identified toxin genes in pathological C. butyricum strains, which is highly relevant to safety and strain selection, but this is not human pharmacogenomics.
Conclusion: based on these abstracts, there is no direct evidence that C. butyricum’s effects are beneficial or harmful specifically in people with particular genetic variants; the most actionable “genetic” consideration described is microbial strain genetics (toxigenic vs non-toxigenic strains).
References
-
Butyrate-producing human gut symbiont,Clostridium butyricum, and its role in health and disease
Magdalena K Stoeva, Jeewon Garcia-So, Nicholas Justice, Julia Myers, Surabhi Tyagi (2021) -
Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota.
Danfeng Chen, Duochen Jin, Shumin Huang, Jingyi Wu, Mengque Xu, Tianyu Liu, Wenxiao Dong, Xiang Liu, Sinan Wang, Weilong Zhong, Yi Liu, Ruihuan Jiang, Meiyu Piao, Bangmao Wang, Hailong Cao (2020) - Cancer letters -
Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021.
Agam K Rao, Jeremy Sobel, Kevin Chatham-Stephens, Carolina Luquez (2021) - MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports -
Clostridium butyricum and Its Derived Extracellular Vesicles Modulate Gut Homeostasis and Ameliorate Acute Experimental Colitis.
Lingyan Ma, Qicheng Shen, Wentao Lyu, Lu Lv, Wen Wang, Minjie Yu, Hua Yang, Shiyu Tao, Yingping Xiao (2022) - Microbiology spectrum -
Anti-Inflammatory Effect of Clostridium butyricum-Derived Extracellular Vesicles in Ulcerative Colitis: Impact on Host microRNAs Expressions and Gut Microbiome Profiles.
Lingyan Ma, Wentao Lyu, Yuanyuan Song, Kai Chen, Lu Lv, Hua Yang, Wen Wang, Yingping Xiao (2023) - Molecular nutrition & food research -
Effects of Clostridium butyricum on growth performance, metabonomics and intestinal microbial differences of weaned piglets.
Jing Liang, Shasha Kou, Cheng Chen, Sayed Haidar Abbas Raza, Sihu Wang, Xi Ma, Wen-Ju Zhang, Cunxi Nie (2021) - BMC microbiology -
Clostridium butyricum: from beneficial to a new emerging pathogen.
N Cassir, S Benamar, B La Scola (2016) - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases -
Probiotic Roles of
Xiaopeng Tang (2024) - Animals : an open access journal from MDPI -
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors.
Yusuke Tomita, Yoshihiko Goto, Shinya Sakata, Kosuke Imamura, Ayaka Minemura, Kentaro Oka, Atsushi Hayashi, Takayuki Jodai, Kimitaka Akaike, Moriyasu Anai, Shohei Hamada, Shinji Iyama, Koichi Saruwatari, Sho Saeki, Motomichi Takahashi, Tokunori Ikeda, Takuro Sakagami (2022) - Oncoimmunology -
Clostridium butyricum potentially improves inflammation and immunity through alteration of the microbiota and metabolism of gastric cancer patients after gastrectomy.
Wenjie Cao, Cihua Zheng, Xuan Xu, Rui Jin, Feng Huang, Meng Shi, Zhipeng He, Yufeng Luo, Lulin Liu, Zhaoxia Liu, Jing Wei, Xiaorong Deng, Tingtao Chen (2022) - Frontiers in immunology -
Effect ofClostridium butyricumon Gastrointestinal Infections
Tadashi Ariyoshi, Mao Hagihara, Motomichi Takahashi, Hiroshige Mikamo (2022) -
Neuroprotective effect of engineered
Yun Wang, Wen-Jie Chen, Yi-Yang Han, Xuan Xu, Ai-Xia Yang, Jing Wei, Dao-Jun Hong, Xin Fang, Ting-Tao Chen (2023) - Bioengineering & translational medicine -
Health benefits of butyrate and its producing bacterium,
Ngoc Tuan Tran, Huifen Liang, Jinkun Li, Taoqiu Deng, Ming Zhang, Shengkang Li (2023) - Fish and shellfish immunology reports -
Effect of dietary Clostridium butyricum on growth, intestine health status and resistance to ammonia stress in Pacific white shrimp Litopenaeus vannamei.
Yafei Duan, Yue Zhang, Hongbiao Dong, Yun Wang, Xiaoting Zheng, Jiasong Zhang (2017) - Fish & shellfish immunology -
Clostridium butyricum and Chitooligosaccharides in Synbiotic Combination Ameliorate Symptoms in a DSS-Induced Ulcerative Colitis Mouse Model by Modulating Gut Microbiota and Enhancing Intestinal Barrier Function.
Xingxi Huang, Jutuan Hu, Heng Zhang, Ji Li, Xi Zhu, Yangyang Liu, Yunxiang Liang, Yuxia Mei (2023) - Microbiology spectrum -
Interplay between Bile Acids and Intestinal Microbiota: Regulatory Mechanisms and Therapeutic Potential for Infections.
Wenweiran Li, Hui Chen, Jianguo Tang (2024) - Pathogens (Basel, Switzerland) -
Probiotic Potential ofClostridiumspp.-Advantages and Doubts
Tomasz Grenda, Anna Grenda, Piotr Domaradzki, Paweł Krawczyk, Krzysztof Kwiatek (2022) -
Clostridium butyricum Prevents Dysbiosis and the Rise in Blood Pressure in Spontaneously Hypertensive Rats.
Xianshu Luo, Zhuoyu Han, Qing Kong, Yuming Wang, Haijin Mou, Xuefeng Duan (2023) - International journal of molecular sciences -
Cannabinoids modulate the microbiota-gut-brain axis in HIV/SIV infection by reducing neuroinflammation and dysbiosis while concurrently elevating endocannabinoid and indole-3-propionate levels.
Marina McDew-White, Eunhee Lee, Lakmini S Premadasa, Xavier Alvarez, Chioma M Okeoma, Mahesh Mohan (2023) - Journal of neuroinflammation -
Effect of Clostridium butyricum on High-Fat Diet-Induced Intestinal Inflammation and Production of Short-Chain Fatty Acids.
Yonghoon Choi, Soo In Choi, Nayoung Kim, Ryoung Hee Nam, Jae Young Jang, Hee Young Na, Cheol Min Shin, Dong Ho Lee, Huitae Min, Yeon-Ran Kim, Yeong-Jae Seok (2023) - Digestive diseases and sciences
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!